Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 1;34(4):322-327.
doi: 10.1097/CCO.0000000000000853.

Treatment updates on tenosynovial giant cell tumor

Emanuela Palmerini  1 , Eric L Staals  2
Affiliations
Review

Treatment updates on tenosynovial giant cell tumor

Emanuela Palmerini et al. Curr Opin Oncol. .

Abstract

Purpose of review: Diffuse-type tenosynovial giant cell tumor (dt-TGCT) is a benign clonal neoplastic proliferation arising from the synovium. Patients are often symptomatic, require multiple surgical procedures during their lifetime, and have reduced quality of life (QoL). Surgery is the main treatment with relapse rates ranging from 14 to 55%. The treatment strategy for patients with dt-TGCT is evolving. The purpose of this review is to describe current treatment options, and to highlight recent developments in the knowledge of the molecular pathogenesis of dt-TGCT as well as related therapeutic implications.

Recent findings: TGCT cells overexpress colony-stimulating factor 1 (CSF1), resulting in recruitment of CSF1 receptor (CSF1R)-bearing macrophages that are polyclonal and make up the bulk of the tumor, has led to clinical trials with CSF1R inhibitors. These inhibitors include small molecules such as pexidatinib, imatinib, nilotinib, DCC-3014 (vimseltinib), and the monoclonal antibody RG7155 (emactuzumab).

Summary: In conclusion, D-TGCT impairs patients' QoL. The evidence that the pathogenetic loop of D-TGCT can be inhibited has changed the therapeutic armamentarium for this condition. Clinical trials of agents that target CSF1R are currently ongoing. All this new evidence should be taken into consideration within multidisciplinary management.

PubMed Disclaimer

References

    1. de Saint Aubain Somerhausen N, van de Rijn M. Tenosynovial giant cell tumour. In WHO Classification of Tumours Editorial Board ed. World Health Organisation classification of tumours of soft tissue and bone. 5th ed.2020; Lyon: IARC Press, 133–137.
    1. Ottaviani S, Ayral X, Dougados M, et al. Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature. Semin Arth Rheum 2011; 40:539–546.
    1. Siegel M, Bode L, Südkamp N, et al. Treatment, recurrence rates and follow-up of tenosynovial giant cell tumor (TGCT) of the foot and ankle – a systematic review and meta-analysis. PLoS One 2021; 16:e0260795.
    1. Mastboom MJL, Verspoor FGM, Verschoor AJ, et al. Higher incidence rates than previously known in tenosynovial giant cell tumors. Acta Orthop 2017; 88:688–694.
    1. Mastboom MJ, Planje R, van de Sande MA. The patient perspective on the impact of tenosynovial giant cell tumors on daily living: crowdsourcing study on physical function and quality of life. Interact J Med Res 2018; 7:e4.

MeSH terms

Substances